Holman RR, Sourij H, Califf RM Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014, 383:2008-2017.
Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764.
Sun F, Yu K, Wu S, et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 2012, 98:386-395.
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obesity Metab 2014, 16:38-47.
Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJV Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 2015, published online Aug 12. http://dx.doi.org/10.1016/S2213-8587(15)00233-8.
Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies. Diab Vasc Dis Res 2011, 8:237-240.
Wu S, Sun F, Zhang Y, et al. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. J Clin Pharm Ther 2014, 39:7-13.
Seshasai SR, Bennett RL, Petrie JR, et al. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes Obesity Metab 2015, 17:505-510.
Pfeffer MA, and members of the ELIXA executive committee. The evaluation of lixisenatide in acute coronary syndrome-the results of ELIXA. Annual Meeting of the American Diabetes Association; Boston, MA, USA; June 5-9, 2015.
Scheen AJ, Charbonnel B Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 2014, 40:176-185.
